Please try another search
Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.
Name | Age | Since | Title |
---|---|---|---|
Stan E. Abel | 55 | 2019 | Independent Director |
Matthew R. Ruth | 51 | 2019 | Independent Director |
Eckard Weber | 71 | 2019 | Independent Director |
Dennis G. Podlesak | 63 | 2019 | Independent Chairman of the Board |
Richard Orr | 60 | 2010 | President, CEO, Principal Financial Officer & Director |
Gregory J. Flesher | 51 | 2019 | Director |
Julien Mamet | 45 | 2007 | Founder, Chief Scientific Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review